[Signal-transduction therapy].
Hidaka
H
H
Ichikawa
A
A
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000818:Animals; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy*; D011982:Receptors, Prostaglandin; D015398:Signal Transduction; D013927:Thrombosis / Q000188:drug therapy*
D002121:Calcium Channel Blockers; D011982:Receptors, Prostaglandin; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; C049347:fasudil; D002118:Calcium